Caterpillar Inc vs ClearPoint Neuro Inc — how do they compare? Caterpillar Inc trades at $938 (market cap $429.89B), while ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M). The key difference: Caterpillar Inc is far larger — about 898.2× ClearPoint Neuro Inc's market cap, and Caterpillar Inc pays a 0.7% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CAT | CLPT | |
|---|---|---|
Market Cap | $429.89B | $478.63M |
Sector | Industrials | Health |
52-Week High | $1.06K | $29.60 |
52-Week Low | $404.64 | $8.66 |
Enterprise Value | $468.88B | $506.63M |
Dividend Yield | 0.7% | — |
Signals from Pluang's Aura AI — not financial advice
Caterpillar (CAT) trades at $933.34, down 2.0% on the day but up 51% year-to-date, reflecting strong momentum from AI-driven infrastructure demand. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $5.54 surpassing expectations by 19%. Valuation metrics remain elevated with a P/E of 46.39 and P/S of 6.18, while profitability remains robust with a 13.33% net margin and 51.35% ROE. Technical indicators show neutral signals with support at $922 and resistance at $943.
Outlook remains positive with analyst consensus pointing to $1,020 price target (9% upside) and 55% buy ratings. Key opportunities include AI data center power demand generating $10.2B in generator sales, while risks include elevated valuation and cyclical exposure to economic conditions. The company's 32nd consecutive dividend increase expected in June supports income investors.
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Trailing returns across standard periods
Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →